Bio-Rad Q3 revenue $747M (+15.4% YoY); non-GAAP EPS $3.71; raises FY21 guidance

BIO-RAD LABORATORIES, INC.

2021-Q3 EPS reported $192.76 revenue$2,189,776,000

Life Science segment revenue $373.5M (+15.3% YoY); Clinical Diagnostics $372.2M (+15.5% YoY).
GAAP net income $3.93B ($129.96 diluted EPS) driven by $4.87B unrealized gain on Sartorius equity.
Non-GAAP net income $112.2M ($3.71 diluted EPS) vs $90.3M ($3.00) a year ago.
Full-year 2021 guidance: non-GAAP currency-neutral revenue growth 12-13%; operating margin ~19.5%.
Gross margin improved to 58.6% from 56.7%; operating margin 21.0% vs 16.9%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.